Pfizer Inc. $PFE Position Trimmed by Empowered Funds LLC

Empowered Funds LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,017,739 shares of the biopharmaceutical company’s stock after selling 55,019 shares during the period. Empowered Funds LLC’s holdings in Pfizer were worth $28,578,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the 4th quarter valued at approximately $26,000. YANKCOM Partnership acquired a new stake in Pfizer in the fourth quarter worth $28,000. HFM Investment Advisors LLC increased its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the period. Evolution Wealth Management Inc. lifted its stake in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the last quarter. Finally, Abound Financial LLC acquired a new position in shares of Pfizer during the fourth quarter valued at $31,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.6%

NYSE:PFE opened at $24.68 on Tuesday. The stock has a market cap of $140.63 billion, a price-to-earnings ratio of 18.84 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The business has a fifty day moving average of $25.10 and a 200-day moving average of $26.17.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the prior year, the company posted $0.92 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is 131.30%.

Wall Street Analyst Weigh In

PFE has been the subject of several recent research reports. Guggenheim lowered their price target on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Finally, UBS Group restated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.50.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.